Rakesh Gaur, MD
Hematology & Oncology · Merriam, KSNPI 1780630368
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,625 of the $5,461 with a category attached, or 66.4%. Immunocore Limited accounts for 66.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $3,713 and has fallen 71.1% since, to $1,072 in 2025.
Across 27 payments — averaging $202.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$4K
- AstraZeneca$950
- Daiichi Sankyo Inc.$650
- Bristol Myers Squibb$31
- Acrotech Biopharma Inc.$28
- GSK$22
- plus $126 from 7 others
What the payments were for
- Consulting fees$3,62566%
- Speaking & faculty fees$2505%
- Grants$3506%
- Travel & lodging$89816%
- Food & beverage$3106%
- Education$281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 10 | $3,654 |
| AstraZeneca(2 entities) | 4 | $950 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Bristol Myers Squibb | 2 | $31 |
| Acrotech Biopharma Inc. | 2 | $28 |
| GSK | 1 | $22 |
| Amgen | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Novocure Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,461 in reported general payments places this provider in the 65th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 27 | $559,000 |
| CabometyxCabozantinib S-Malate | 14 | $367,991 |
| Lenalidomide | 11 | $179,818 |
| EliquisApixaban | 103 | $83,769 |
| VenclextaVenetoclax | 15 | $54,457 |
| CreonLipase/Protease/Amylase | 20 | $45,998 |
| XareltoRivaroxaban | 16 | $17,634 |
| Fentanyl | 40 | $4,187 |
| Anastrozole | 97 | $2,063 |
| Hydroxyurea | 63 | $1,582 |
| Oxycodone Hcl | 108 | $1,499 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $957 |
| ValacyclovirValacyclovir Hcl | 19 | $937 |
| Gabapentin | 38 | $782 |
| Dexamethasone | 19 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $31 | $559,00027 claims |
| Exelixis Inc.Cabometyx | $20 | $367,99114 claims |
| PfizerEliquis | $20 | $83,769103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Merriam
- Mouhammed KyasaMerriam$3K
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Marc HoffmannOverland Park$153K
- Priyanka SharmaWestwood$135K
- Jeffrey WeitzelKansas City$117K
- Joseph McGuirkKansas City$113K
- Gary DoolittleWestwood$102K
- Dhruv BansalOverland Park$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.